A recent paper has surveyed the policies implemented for pricing and promoting the use of biosimilar medicines across countries in Europe and internationally. It explores the similarities and differences between biosimilar and generic policies [5].

Members of the Pharmaceutical Pricing and Reimbursement Information (PPRI) network completed a survey containing questions relating to the status of generic and biosimilar medicines policies. The focus of the survey was on policies for biosimilar medicines, but it also contained questions relating to generic medicines policies, so that the differences between policies for the two medicine groups could be explored [5].

It emerged that the most common method for pricing generic and biosimilar medicines is to set their prices at a defined percentage below their originator price. Out of 40 European countries, Canada and South Africa, 30 used this method for pricing generics and 15 used it for pricing biosimilars. In all but six of these countries, the required difference between originator and biosimilar medicine price, was less than for generics.

When it comes to other specific pricing policies, in many countries tendering procedures are used for off-patent medicines. These appear to be effective in generating savings for payers. However, in many cases biosimilars have only recently been included in tenders and in most cases these are hospital tenders and they have been rarely applied to the outpatient sector. This is in line with the results of the first European Biopharmaceutical Enterprises (EBE) study on pricing and reimbursement policies for biological medicines [6].

The practice of substitution refers to the dispensing of one medicine instead of another equivalent and interchangeable medicine at the pharmacy level without consulting the prescriber. It was revealed that generics substitution is in place in 37 out of 42 of the surveyed countries. This is in keeping with finding from the second European Biopharmaceutical Enterprises (EBE) study [7] and Pfizer’s survey to investigate pharmacy-mediated substitution [8]. However, substituting with biosimilar medicines for an originator biological medicine is not applied widely at pharmacy level. This is only seen to occur in some countries in Central and Eastern Europe.

Overall, the study has revealed that pricing policies and instruments to enhance the uptake of generics are advanced. However, work needs to be done to see the same uptake success with biosimilars and an appropriate approach needs to be more widely adopted.  

Editor’s comment
Readers interested to learn more on pricing of biosimilars are invited to visit www.gabi-journal.net to view the following manuscripts published in GaBI Journal:

Pricing of biosimilars in Saudi Arabia

GaBI Journal is indexed in Embase, Scopus, Thomson Reuters’ ESCI, and more.

Contribute a research or review paper to GaBI Journal – an independent, peer reviewed academic journal – send us your submission here.

Related articles
The Greek problem of generics pricing

Price/access expected to be major drivers for biosimilars uptake

References
1.  Vogler S. The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries–an overview. Generics and Biosimilars Initiative (GaBI Journal). 2012;1(2):93-100. doi:10.5639/gabij.2012.0102.020
2. Simoens S. A review of generic medicine pricing in Europe. Generics and Biosimilars Initiative (GaBI Journal). 2012;1(1):8-12. doi:10.5639/gabij.2012.0101.004
3. Vogler S, Zimmermann N. How do regional sickness funds encourage more rational use of medicines, including the increase of generic uptake? A case study from Austria. Generics and Biosimilars Initiative Journal (GaBI Journal). 2013;2(2):65-75. doi:10.5639/gabij.2013.0202.027
4. Godman B, Wettermark B, Bishop I, Burkhardt T, Fürst J, Garuoliene K. European payer initiatives to reduce prescribing costs through use of generics. Generics and Biosimilars Initiative Journal (GaBI Journal). 2012;1(1):22-7. doi:10.5639/gabij.2012.0101.007
5. Vogler S, Schneider P. Do pricing and usage-enhancing policies differ between biosimilars and generics? Findings from an international survey. Generics and Biosimilars Initiative Journal (GaBI Journal). 2017;6(2):79-88. doi:10.5639/gabij.2017.0602.015
6.  Acha V, Allin P, Bergunde S, Bisordi F, Roediger A. What pricing and reimbursement policies to use for off-patent biologicals? – Results from the EBE 2014 biological medicines policy survey. Generics and Biosimilars Initiative Journal (GaBI Journal). 2015;4(1):17-24. doi:10.5639/gabij.2015.0401.006
7. Reiland JB, Freischem B, Roediger. What pricing and reimbursement policies to use for off-patent biologicals in Europe? – results from the second EBE biological medicines policy survey. Generics and Biosimilars Initiative Journal (GaBI Journal). 2017;6(2):61-78. doi:10.5639/gabij.2017.0602.014
8.  Larkin H, Macdonald J, Lumsden R. Pharmacy-mediated substitution of biosimilars – a global survey benchmarking country substitution policies. Generics and Biosimilars Initiative Journal (GaBI Journal). 2017;6(4):157-64. doi:10.5639/gabij.2017.0604.034

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2018 Pro Pharma Communications International. All Rights Reserved.